- Qing Ma, University at Buffalo (more)
Collaborators and Expertise
- David Haas, Vanderbilt University, Pharmacogenomics (more)
- Scott Letendre, University of California San Diego, Infectious Disease, Neurocognitive Disorders (more)
- Supriya Mahajan, University at Buffalo, Neuroimmunology (more)
- Giovanni Schifitto, University of Rochester, Neuroimaging (more)
- Bing Su, University at Buffalo, Substance Use Disorder, Toxicology (more)
- Charles Venuto, University of Rochester, Clinical Pharmacology (more)
We focus on pharmacological mechanisms underlying HIV-associated neurocognitive disorders and mental health issues, as well as the optimization and development of pharmacological interventions potentially used to treat these conditions.
- Neurological disorders in the elderly have been identified as a critical challenge in the context of HIV infection. HIV-associated neurocognitive disorders affect up to 70% of HIV-infected individuals and is associated with a lower quality of life and a serious threat to human health. Even though the development of potent antiretroviral therapy is considered one of the greatest accomplishments of medicine which greatly extended the life expectancy, in the past two decades, there has been a marked increase in the incidence of neurological disorders among people living with HIV. Unfortunately, there is a remarkable lack of understanding of the pathogenesis or a strategy to develop effective therapeutic interventions. Importantly, research on neurological comorbidities and substance use disorders has become a priority.
- Our focus has been an integrated approach to address this very difficult problem involving translational pharmacology, neurocognitive assessment, genetics, and pharmacokinetics to optimize the beneficial effects of combination antiretroviral therapy in the central nervous system and apply our experiences to the development of new regimens for treatment and prevention of neurological complications of HIV. These questions are being addressed in the laboratory and small clinical trials, however, the results cannot be extrapolated to a more complex patient population. The gaps between the drug development literature and clinical practice serve as a continuous stimulus for translational research. Given the multiple challenges faced by people living with HIV as they age, there are numerous opportunities for optimizing anti-HIV medication use and treatment outcomes.
Connections to the ACTG Neurology Collaborative Science Group
- Translational Neuropharmacology Group members have served the ACTG Neurology Collaborative Science Group and other Groups as the Chair, Investigators, and Pharmacologists.
Connections to the Center for Health + Technology (CHeT)
- Translational Neuropharmacology Group members serve the CHeT as faculty members.
- Major clinical studies: Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation https://doi.org/10.1016/S1474-4422(17)30328-9
Learn more about the group here: https://www.urmc.rochester.edu/health-technology.aspx